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Abstract
Background—The development of non-syndromic congenital heart defects (CHDs) involves a
complex interplay of genetics, metabolism, and lifestyle. Previous studies have implicated
maternal single nucleotide polymorphisms (SNPs) and altered metabolism in folate-related
pathways as CHD risk factors.
Objective—We sought to discover associations between maternal SNPs and metabolites
involved in the homocysteine, folate, and transsulfuration pathways, and determine if these
associations differ between CHD cases and controls.
Design—Genetic, metabolic, demographic, and lifestyle information was available for 335
mothers with CHD-affected pregnancies and 263 mothers with unaffected pregnancies. Analysis
was conducted on 1160 SNPs, 13 plasma metabolites, and 2 metabolite ratios. A two-stage
multiple linear regression was fitted to each combination of SNP and metabolite/ratio.
Results—We identified 4 SNPs in the methionine adenosyltransferase II alpha (MAT2A) gene
that were associated with methionine levels. Three SNPs in tRNA aspartic acid methyltransferase
1 (TRDMT1) gene were associated with total plasma folate levels. Glutamylcysteine (GluCys)
levels were associated with multiple SNPs within the glutathione peroxidase 6 (GPX6) and O-6-
methylguanine-DNA methyltransferase (MGMT) genes. The regression model revealed
interactions between genotype and case-control status in the association of total plasma folate,
total glutathione (GSH), and free GSH, to SNPs within the MGMT, 5,10-methenyltetrahydrofolate
synthetase (MTHFS), and catalase (CAT) genes, respectively.
Conclusions—Our study provides further evidence that genetic variation within folate-related
pathways accounts for inter-individual variability in key metabolites. We identified specific SNP-
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metabolite relationships that differed in mothers with CHD-affected pregnancies, compared to
controls. Our results underscore the importance of multifactorial studies to define maternal CHD
risk.
INTRODUCTION
Congenital heart defects (CHDs) are the most prevalent of all structural birth defects,
occurring in 8 to 11 of every 1000 live births [1, 2]. Multiple genes have been implicated in
CHD development [3], but for the majority of infants diagnosed with a CHD, an established
causative gene or teratogenic agent cannot be identified [4, 5]. The majority of CHDs are
non-syndromic and are thought to result from a complex interplay between genetic and
epigenetic susceptibilities, and parental environmental, lifestyle, and endogenous factors [6].
Due to strong evidence that maternal intake of folic acid supplements reduces the risk of
CHDs [6, 7], multiple research studies have focused on the identification of genetic and
metabolic risk factors within folate metabolism that are associated with CHDs.
Previous work by our research group and others have described an association between
CHDs and alterations in maternal plasma metabolites involved in folate metabolism [8–12].
Studies attempting to identify common genetic variants in genes encoding enzymes involved
in folate metabolism associated with an increased risk of CHDs have yielded inconsistent
results [13–16]. However, the associations between common genetic variants and plasma
metabolites in folate metabolism, and their potential associations with CHDs, remain
relatively unexplored.
Nutrigenomics has been defined as the study of how genetic variants influence metabolism
and is a rapidly developing field in the study of complex diseases [17]. Compared to strictly
genomic studies, combining metabolic and genetic data for nutrigenomic studies (a)
provides biochemical measurements which may provide details more directly related to the
disease, while (b) genetic variants associated with changes in metabolic homeostasis may
provide insight into the pathophysiology of disease [18]. Genome-wide association (GWA)
studies have identified and/or verified single nucleotide polymorphisms (SNPs) associated
with a few key metabolites involved in folate metabolism [19–22]. However, the majority of
large population nutrigenomic studies have not focused on identifying gene-metabolite
relationships associated with a particular disease state.
It has become abundantly clear that multifactorial analysis is crucial in determining the risk
of complex diseases such as CHDs. We hypothesize that certain maternal common genetic
variants are associated with plasma metabolites involved in folate metabolism, and
examined the association between 1160 SNPs in 62 genes and 15 selected metabolites and
metabolite ratios involved in three key folate-related pathways. We also sought to determine
if these associations differed in women who gave birth to infants with a CHD compared to
healthy controls.
SUBJECTS AND METHODS
Study Population
All study subjects were enrolled in the National Birth Defects Prevention Study (NBDPS),
an ongoing multi-site population-based case-control study to investigate the etiology of 30
non-syndromic birth defects. The NBDPS is the largest case-control study of birth defects
ever conducted in the U.S. The study population and eligibility criteria for the NBDPS have
been previously outlined [23]. Briefly, subjects were identified through population-based
birth defect surveillance systems in 9 states. For the current study, cases are defined as
Arkansas mothers who delivered a singleton live birth with a CHD, and participated in a
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follow-up study that involved a home visit. Cases in which the pregnancy was also affected
by a known single-gene disorder, chromosomal abnormality, or syndrome were excluded.
All diagnostic tests, including echocardiograms, cardiac catherizations, surgical and autopsy
reports, on Arkansas NBDPS case infants with cardiac defects were reviewed by a pediatric
cardiologist to ensure that uniform criteria were used for diagnoses. Using a classification
system developed for the NBDPS, which incorporated three dimensions of cardiac
phenotype, cardiac complexity, and extracardiac anomalies [24], case women for the current
study included those who carried fetuses with at least one cardiac lesion, including
conotruncal, septal, and/or obstructive lesions. Controls were those women who had a
singleton live birth without birth defects during the same period as cases, who participated in
the NBDPS, and were randomly selected from birth certificate data or hospital discharge
logs. Case and control mothers spoke either English or Spanish. All study participants
submitted buccal cell samples and/or peripheral blood, from which DNA was isolated and
plasma metabolites were measured. The study was approved by the University of Arkansas
for Medical Sciences’ Institutional Review Board and the NBDPS with protocol oversight
by the Centers for Disease Control and Prevention (CDC) Center for Birth Defects and
Developmental Disabilities. All of the study subjects gave written informed consent, with
recruitment commencing in 1998. Finally, women who were pregnant at time of phlebotomy
or who had a genotyping call rate <80% were excluded from analysis. The analytical data
set used in statistical models contained 335 cases and 263 controls.
Collection of DNA from buccal cell and peripheral blood samples
Methods for NBDPS biologic sample acquisition and processing are well-established [25].
Once a mother has completed the interview, a sample collection kit (containing instructions,
consent forms, sterile brushes, reimbursement, and return envelope) is mailed. Blood
samples were collected by research nurses during home visits in Arkansas.
Maternal Interview and Home Visit Data
Collection of other covariates has been previously described by our research group [26].
Information regarding selected lifestyle factors were obtained by research nurses using a
structured computer-assisted telephone interview and a Block Abbreviated Food-Frequency
Questionnaire [27]. After NBDPS participation, each CHD-eligible and control mother
participant was contacted by telephone to schedule a home visit. During home visits, the
nurse obtained written consent, performed venipuncture to obtain blood, and collected
information about current use of multivitamins, cigarettes, alcohol, and caffeine. The
selected patient characteristics are listed and summarized in Table 1.
Biochemical measurements
We have previously reported on plasma concentrations of biomarkers in the folate and
transsulfuration pathways [8, 9, 26]. Methods for sample preparation and measurement of 14
selected metabolites have been described previously [28, 29]. The metabolites included in
the current study are listed and summarized in Table 2. We included all Arkansas NBDPS
participants for which metabolite and genetic data had been collected.
Selection of candidate genes and SNPs
Selection of candidate genes was based on the following three inclusion criteria: 1) the gene
encodes an enzyme in one of the three candidate metabolic pathways (folate, homocysteine
or transsulfuration pathways), as indicated by an advanced search of HumanCyc, a Pathway/
Genome Database [30], which is part of the MetaCyc Database Collection [31] and allows
human metabolic processes to be viewed within the context of the annotated human genome;
2) the candidate gene is expressed in liver and/or heart tissue [30], and 3) the identity of the
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gene is validated by a search of the National Center for Bioinformatics (NCBI) databases
[32]. Sixty-two genes that met the above inclusion criteria were chosen and are listed in
Table 3.
Haplotype-tagging SNP Selection
Using data from Phase I and Phase II of the International HapMap Project, we have selected
a maximally informative set of haplotype-tagging SNPs (htSNPs) for each of the selected 62
candidate genes using an algorithm based on the linkage disequilibrium statistic r2 [33]. For
each gene, htSNPs were chosen from the entire gene region (including introns) with
additional 10-kb flanking sequences. To choose htSNPs, pairwise r2 values were computed
for each marker combination within 200 kb for loci with a minor allele frequency (MAF)
>0.10 in each population studied. In collaboration with Illumina, htSNPs were chosen based
on an Illumina assay design score. SNPs having the highest GoldenGate assay design scores
were assigned to haplotype bins using an Illumina proprietary algorithm to predict genotype
success. The algorithm provided an overall score that ranges from 0–1 and is based on the
predicted optimal oligonucleotide probe sequences for each marker. The oligonucleotide
sequences were evaluated for characteristics that include G–C content, melting temperature,
self-complementarity, and uniqueness in the genome.
Using these algorithms, a set of htSNPs were selected for inclusion in a customized Illumina
GoldenGate genotyping panel. The customized SNP Panel, referred to as an Oligo Pool All
(OPA), included a total of 1536 SNPs.
DNA extraction and quantification
DNA was extracted from buccal cell samples and peripheral blood by use of Pure Gene
DNA purification reagents (Qiagen, Valencia, CA) according to the manufacturer’s
protocol, and was quantified by use of the Applied Biosystems (Applied Biosystems, Foster
City, CA) TaqMan RNaseP Detection Reagents using a standard curve of DNA of known
concentration. Standard curve and DNA samples from case and control subjects were
subjected to an initial denaturation at 95°C for 10 min followed by 40 cycles of polymerase
chain reaction (PCR) of 95°C for 15 sec and 60°C for 1 min in an ABI PRISM 7900HT real-
time PCR instrument. DNA concentrations were calculated from the standard curve using
ABI software.
Whole genome amplification
The DNA isolated from buccal cells (10 to 15 ng) was used as a template for whole genome
amplification (WGA) by use of the GenomePlex WGA kit according to the protocol
provided by the manufacturer (Sigma, St. Louis, MO). The resultant WGA product was
quantified as above and 200 ng were used for genotyping in the Illumina Golden Gate assay.
The merits of using whole genome amplified DNA in microarray platforms have been
previously shown [34].
Genotyping by Illumina Golden Gate Assay
SNP genotyping was conducted using 200 ng (40 ng/µl) of study subject WGA amplified
DNA using the Illumina Golden Gate platform [35] and the previously described custom
panel of 1536 SNPs in 62 target genes in the folate, homocysteine, and transsulfuration
pathways. Genotype analysis was conducted using the Golden Gate assay protocol supplied
by Illumina. BeadChips were scanned on the Illumina BeadArray Reader and initial
genotype calls were generated using GenCall, Illumina’s proprietary genotyping algorithm.
Among the 1536 SNP intensity plots, we observed a varying quality of genotype clustering,
with the majority of SNPs displaying three well-segregated genotype clusters, but with a
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large number of SNPs clustering poorly; this same behavior was observed in a test set of
blood samples. The initial calls, plus the raw intensity data, were therefore used as inputs to
SNPMClust, a bivariate Gaussian model-based genotype-clustering and -calling algorithm
developed in-house. SNPMClust is an extension of MClust [36], a contributed package in
the R statistical computing environment [37], and provides a quantitative measure of
genotype-calling uncertainty, which was used to distinguish calls from no-calls. After
running SNPMClust on all 1536 SNPs, clustering and classification plots were visually
inspected, in some cases leading to dropping a SNP from analysis or applying SNPMClust
under non-default settings.
Statistical analysis
SNPs with call rates <90%, SNPs that significantly deviate by race from Hardy– Weinberg
equilibrium (p<10−4) [38], and SNPs that are monomorphic in our samples were excluded
from further analysis. As stated earlier, subjects with call rates <80% of SNPs were also
dropped from analysis. This resulted in an analysis data set of 1160 SNPs for 335 case
mothers and 263 control mothers.
We initially tested for SNP/metabolite associations assuming three different modes of
inheritance (additive, dominant, and recessive), and each of the three models identified
different sets of significant SNPs. Lettre et al. [39] have shown that the codominant, or
“genotypic”, model retains nearly optimal statistical power under all three modes of
inheritance, even though it is a general model that makes no assumptions about the
contribution of each additional risk allele. By using a single test of association, furthermore,
there is no need to adjust for the bias that is introduced by running three models and then
choosing the most significant result. All of the association results we present, therefore,
were generated under the co-dominant model.
Our previous research [26] has shown significant associations between CHD status and
multiple metabolites in the folate pathway. Case-control status was therefore included as a
dummy variable in all of the association analysis. We also observed multiple SNP/
metabolite associations with non-additive interactions between genotype and disease status;
that is, instances where the magnitude, or even direction, of genetic association differs
between cases and controls. Simultaneously testing for association and interaction, however,
reduces the statistical power to detect associations in the absence of interactions. We
therefore implemented a model selection procedure, in which genotype/case-control
interaction terms were included in the model only if a likelihood ratio test found these terms
to be significant at p<0.01. Additional environmental and behavioral variables included in
the model were age, BMI, race, interval between birth and phlebotomy, nursing status,
smoking status, drinking status, and vitamin-intake status at time of phlebotomy.
To account for the large number of statistical tests being performed, false discovery rate
(FDR) q-values [40] were computed for each SNP on a metabolite-bymetabolite basis. In
our context, FDR is defined as the proportion of detected SNPs that are, in truth, not
associated with the metabolite, while the q-value is defined as the minimum FDR at which a
given test can be considered significant. The q-value is thus the FDR equivalent of the p-
value and was computed using the qvalue package in the R statistical programming
environment [37]. We also produced quantile-quantile (Q-Q, WTCCC 2007) plots of
−log10(p-values), which allow visual inspection of the distribution of p-values across all
SNPs. Deviations above the dotted line of equality indicate a distribution of p-values more
heavily weighted toward zero than expected under the null hypothesis of no genetic
association. Statistical analysis was performed in the R statistical programming environment
(37).
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RESULTS
Patient characteristics
A total of 335 cases (mothers with CHD-affected pregnancies) and 263 control mothers
were included in the study. Patient characteristics are summarized in Table 1. Briefly, post-
pregnancy (at time of home visit and phlebotomy) alcohol drinking tended to be more
prevalent (p=0.064) in cases (71.9%) than in controls (63.5%). A higher proportion
(p=0.073) of case mothers tended to be overweight (25.7%) compared to the control
population (20.5%), consistent with previously published analysis of NBDPS data [41]. The
prevalence of vitamin supplementation and smoking was not significantly different in cases
compared to controls.
Plasma metabolite and SNP summary with quality control
The 13 metabolites (and 2 metabolite ratios) with their corresponding means and standard
deviations are summarized in Table 2. Plasma metabolites did not display a normal
distribution, thus all metabolites were log-transformed prior to analysis. Comparisons
between cases and controls agreed with our previously reported findings that alterations in
maternal plasma metabolites are associated with CHDs. For genetic analysis, a custom
Illumina GoldenGate Panel consisting of 1536 SNPs in 62 genes involved in the
homocysteine-homocysteine, folate, and transsulfuration pathways was assayed (Table 3).
As described above, 1160 SNPs met our quality control standards and were included in the
statistical analysis.
SNP and metabolite associations
The first goal of the present study was to determine associations between the 1160 SNPs and
13 metabolites (and 2 metabolite ratios) involved in three key folate-related pathways for the
entire sample population (cases and controls). The top 20 associations for each metabolite
are listed in Supplemental Table 1. Quantile-quantile (Q-Q) plots were generated for each
metabolite and are displayed in Supplemental Figure 1. The Q-Q plots provide visual
evidence that multiple metabolites have significant SNP associations. Figure 1 displays a
Manhattan plot for each metabolite, showing the −log10(p-value) vs. the physical location of
each SNP, and highlighting associations grouped within specific genes and gene families.
The grouping of multiple significant SNPs within genes reflect patterns of linkage
disequilibrium (LD) in nearby loci.
Among the top 20 SNP associations for plasma methionine, 2 SNPs (rs933271, rs174675)
were present in the catechol-O-methyltransferase (COMT) gene, and 4 SNPs (rs2028898,
rs762684, rs17026447, rs17026396) resided in the methionine adenosyltransferase II alpha
(MAT2A) gene. Both genes are involved in the homocysteine pathway. The most significant
associations for adenosine levels included 2 SNPs (rs1801394, rs162027) in the methionine
synthase reductase (MTRR) gene. Both adenosine and the MTRR gene are involved in the
homocysteine pathway. Homocysteine levels were associated with 2 SNPs (rs9621049,
rs4820886) in the transcobalamin II (TCN2) gene, and 2 SNPs (rs2042235, rs8177427) in
the glutathione peroxidase 3 (GPX3) gene. Additionally, 3 of the top 4 associations for total
plasma folate levels included SNPs (rs12241572, rs11254397, rs7085709) in the tRNA
aspartic acid methyltransferase 1 (TRDMT1) gene.
For metabolites in the transsulfuration pathway, multiple associations were also observed.
Within the top 20 associations for glutamylcysteine (GluCys) levels, 6 SNPs (rs2859355,
rs406113, rs1002259, rs974334, rs4713167, rs2859358) are located in the glutathione
peroxidase 6 (GPX6) gene, and 6 SNPs (rs9971190, rs9299872, rs7080570, rs11016857,
rs7923750, rs7098295) within the O-6-methylguanine-DNA methyltransferase (MGMT)
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gene. GluCys and the GPX6 gene are both involved in antioxidant processes in the
transsulfuration pathway. Free GSH levels were associated with 5 SNPs in the glutathione
S-transferase alpha (GSTA) family of enzymes. The associations included 3 SNPs in the
GSTA3 gene (rs641019, rs1052661, rs9463842), 1 SNP (rs6902065) in the GSTA2 gene,
and 1 SNP (rs654144) in the GSTA4 gene. For the ratio of reduced and oxidized glutathione
(GSH/GSSG), a measure of cellular redox potential, 5 SNPs (rs2975138, rs2975139,
rs7294985, rs6488840, rs11056890) in the microsomal glutathione S-transferase 1 (MGST1)
gene were included among the top 20 associations. Taken together, the described results
lend further evidence that SNPs located in genes involved in folate metabolism are
associated with plasma metabolites in the homocysteine, folate, and transsulfuration
pathways.
Among all metabolites, only two SNPs achieved an FDR q-value < 0.05, namely, two
adjacent SNPs (rs3797546, rs16876528) in the betaine-homocysteine methyltransferase
(BHMT) gene that were significantly associated with reduced total glutathione (GSH).
Further inspection revealed that these associations were primarily due to a single patient
with the lowest observed GSH in our sample and the homozygous minor allele genotype at
both SNPs; we therefore treat this result with reservations for the time being.
Investigation of case-control and genotype interactions
One goal of this study was to determine if the relationship between specific SNPs and
metabolites differed between cases and controls. As described in the Statistical Analysis
section of Methods, each combination of metabolite and SNP was tested for a non-additive
interaction between genotype and case/control status, and plots of three illustrative findings
are shown in Figure 2. In Figure 2a, higher folate levels were observed among controls for
the homozygous minor genotype (GG) at SNP rs10764896, located in the MGMT gene, than
for the two other genotypes. The opposite trend was observed in cases (p=0.0012, see
Supplemental Table 1), as the homozygous GG genotype had lower folate levels. In Figure
2b, free GSH levels in controls with the minor AA genotype at SNP rs2733103, located
within the methenyltetrahydrofolate synthetase (MTHFS) gene, were lower than both other
genotypes. The same pattern was observed among cases, but with a greater difference
(p=0.0061). Finally, in Figure 2c, controls possessing the homozygous minor TT genotype
at SNP rs564250, in the catalase (CAT) gene, had lower total GSH levels compared to the
other two genotypes, while controls show the opposite pattern (p=0.0008). These and several
other interactions between case-control status and genotype (Supplemental Table 1) provide
evidence that multiple SNP-metabolite associations do indeed differ depending on CHD
status.
DISCUSSION
Our study builds on previous ones that have shown that maternal SNPs and metabolites
involved in folate metabolism are associated with CHDs. In a recent study, we showed that
elevated homocysteine, decreased methionine, and reduced GSH/GSSG ratio were
significant factors in discriminating between CHD case and control mothers [26]. The goal
of the current study is to 1) investigate the relationship between 1160 maternal SNPs, 13
metabolites, and 2 metabolite ratios involved in folate metabolism and 2) determine if any
associations between maternal SNPs and metabolites differ between cases and controls. The
study represents a comprehensive investigation combining both genetic and metabolic data
in CHDs. Our study differs from previous ones, in that we not only investigated gene-
metabolite associations in our population, but determined if particular SNP-metabolite
associations differed in mothers with CHD-affected pregnancies compared with controls.
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The associations observed in our study include genes and metabolites in three key
interconnected pathways involved in folate metabolism. Multiple SNPs in COMT and
MAT2A were found to be associated with methionine levels. Methionine is an essential
amino acid, crucial in synthesis of methyl groups for methyltransferase reactions. COMT is
involved in vascular and metabolic homeostasis and has been shown to interact with
methylenetetrahydrofolate reductase (MTHFR), a key enzyme in folate metabolism [42]. It
is postulated that the association between MTHFR and COMT may exist because MTHFR
modulates the availability of methyl groups, which are the cosubstrate for COMT reactions.
MATs are involved in the synthesis of SAM from methionine [43], and SNPs within the
MATs have been implicated in hypertension [44]. The top 2 SNPs (rs9621049, rs4820886)
associated with homocysteine levels were found within the TCN2 gene. The rs9621049 SNP
results in an amino acid change from serine to phenylalanine (S348F), which has not yet
been correlated with enzyme activity. Both rs9621049 and rs4820886 were investigated in a
recent study that implicated TCN2 genetic variation in homocysteine levels, but neither SNP
was found to be significantly associated [45]. Elevated homocysteine, a key metabolite in
folate metabolism, has been associated with a variety of disease states including
cardiovascular disease, Alzheimer’s disease, osteoporosis, and birth defects including CHDs
[46]. Previous studies have discovered that genetic variation within the TCN2 gene is
associated with plasma homocysteine concentrations [47]. We found that multiple SNPs
within TRDMT1 were associated with plasma folate levels. TRDMT1 codes for a
methyltransferase that methylates the aspartic acid transfer RNA [48]. A previously reported
study observed an association between genetic variation within TRDMT1 and spina bifida,
and found the same variant was associated with red blood cell folate levels [49].
Multiple associations at SNPs in the GPX6 and MGMT genes were observed for
glutamylcysteine (GluCys). Both genes are thought to be involved in the prevention of DNA
damage and oxidative stress, and GluCys represents a key intermediate in the conversion of
cysteine to glutathione, an important cellular antioxidant metabolite. Six SNPs in GPX6 and
MGMT were associated with GluCys levels. The GPX family of genes is instrumental in the
scavenging of reactive oxygen species (ROS) that could arise from oxidative insults, and
genetic variation within GPX6 may alter glutathione metabolism. SNPs in the GPX gene
family have been shown to alter enzyme activity and increase the risk of thrombotic events
[50]. Although the direct link between SNPs in the MGMT gene and GluCys remains
unclear, previous studies have investigated the relationship between antioxidant mechanisms
and MGMT gene expression [51].
Free glutathione levels (GSH) are essential in antioxidant mechanisms [52]. Five SNPs in
the GSTA gene family were associated with free GSH concentrations. GSTA is involved in
detoxification mechanisms through conjugation with GSH [53]. Thus, SNPs within GSTA
genes may influence glutathione metabolism.
We investigated whether the relationship between specific SNPs and metabolites differed
between cases and controls. Due to the complexity of cardiogenesis, it is plausible that both
genetic and metabolic insults may be involved in CHD development. As shown in Figure 2,
lower total plasma folate and lower free GSH were observed for the homozygous minor
genotype for SNPs in MGMT (rs10764896) and MTHFS (rs2733103), respectively, in
cases. The direction of the metabolic alterations in case mothers are in agreement with our
research group’s previous findings of perturbations in maternal folate metabolism being
associated with CHDs [8, 9, 26]. The association of lower free GSH in case mothers
possessing the minor genotype for MTHFS (rs2733103) is in agreement with the hypothesis
that alterations in methionine metabolism may lead to decreased cycle turnover, and may
ultimately lead to decreased glutathione synthesis [52]. MTHFS is a key enzyme involved in
the folate pathway that metabolizes formyltetrahydorolate. The folate pathway is
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interconnected with methionine metabolism by providing the methyl groups for the
remethylation of homocysteine back to methionine. SNPs within MTHFS, furthermore, have
been associated with non-syndromic cleft lip and palate [54].
A few limitations should be noted. First, maternal blood was drawn after pregnancy, and
metabolite levels measured in the study may not be reflective of metabolism during
cardiogenesis. Multiple studies have shown, however, that homocysteine concentrations and
dietary patterns remain relatively stable from preconception throughout pregnancy and
postpartum [55, 56]. Second, we investigated only common genetic variants in folate
metabolism. Other associations might be observed with the inclusion of rare variants,
additional genes in folate metabolism, and other metabolites related to folate metabolism.
Third, our study included only mothers and not offspring. Identification of genetic risk
factors is complicated by the fact that both maternal and fetal genetic susceptibilities may
affect the intrauterine environment during gestation and contribute to the development of
CHDs [57, 58]. Nevertheless, assessing maternal factors in CHDs is crucial, as the
developing fetus requires the maintenance of homeostasis in the maternal environment.
Maternal genetic associations, furthermore, may aid in assessing preconception risk and be
amenable to targeted clinical intervention. An additional limitation of the study is that our
case study population consists of a heterogeneous class of CHDs. It is possible that certain
genemetabolite interactions may be specific to particular CHD phenotypes (i.e. conotruncal,
obstructive, septal) and were not found in this study. Finally, only two SNP/metabolite
associations achieved an FDR q-value < 0.05. Although patterns observed in the Manhattan
and Q-Q plots (Figure 1 and Supplemental Figure 1) give strong evidence of multiple,
genuine associations, the relatively modest sample size prevented this study from reaching
the most stringent standards of multiplicity-adjusted Type I error control. Independent
replication of our findings will be important to verify the associations identified in our study.
Our study nevertheless represents the most comprehensive investigation to date on the role
of maternal SNPs and metabolites in the occurrence of CHDs, and future studies that
consider the complex pathophysiology of the formation of CHDs may lead to the discovery
of novel risk factors. The discovery of associations between genes and metabolites involved
in folate metabolism provides insight into genetic and metabolic profiles associated with
CHDs, and may implicate potential mechanisms involved in CHD development. Expansion
of nutrigenomic studies in CHDs is warranted, as it becomes clear that a combination of
multiple risk factors is involved in the development of non-syndromic CHDs.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Abbreviations
BHMT betaine-homocysteine methyltransferase gene
CAT catalase gene
CHDs congenital heart defects
COMT catechol-O-methyltransferase gene
FDR false discovery rate
GluCys glutamylcysteine
GPX3 glutathione peroxidase 3 gene
GPX6 glutathione peroxidase 6 gene
GSH glutathione
GSTA glutathione S-transferase alpha
GSTA2 glutathione S-transferase alpha 2 gene
GSTA3 glutathione S-transferase alpha 3 gene
GSTA4 glutathione S-transferase alpha 4 gene
GWA genome-wide association
htSNPs haplotype-tagging SNPs
MAF minor allele frequency
MAT2A methionine adenosyltransferase II alpha
MGMT O-6-methylguanine-DNA methyltransferase gene
MGST microsomal glutathione S-transferase 1 gene
MTHFRI methylenetetrahydrofolate reductase
MTHFS 5,10-methenyltetrahydrofolate synthetase gene
MTRR methionine synthase reductase gene
NBDPS National Birth Defects Prevention Study
PCR polymerase chain reaction
ROS reactive oxygen species
SAM s-adenosylmethionine
SNPs single nucleotide polymorphisms
TCN2 transcobalamin II gene
TRDMT1 tRNA aspartic acid methyltransferase 1 gene
WGA whole genome amplification
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Highlights
We investigate maternal genetic variation and metabolism in congenital heart
defects.
Maternal SNPs and metabolites involved in folate metabolism were analyzed.
Multiple associations were found between maternal SNPs and metabolites.
Interactions between SNPs and metabolites were dependent on case-control status.
Results underscore the importance of multifactorial studies to define CHD risk.
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Figure 1. Manhattan plots
Each Manhattan plot shows the −log10(p-value) resulting from a two-stage test of genetic
association between each of 1160 SNPs and a given metabolite or metabolite ratio, as
described in the text. SNPs are plotted in order of physical location within the genome, and
gene-specific associations of interest are highlighted.
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Figure 2. Three associations with genotype/case-control interactions
Mean (+/− 95% CI) metabolite levels, stratified by case-control status and genotype, are
given for (2A) total plasma folate and rs10764896 (MGMT), (2B) free GSH and rs2733103
(MTHFS), and (2C) total GSH and rs564250 (CAT). Each association contains a statistically
significant interaction (p<0.01) between genotype and case-control status, as determined by
a likelihood ratio test.
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Table 1
Subject Characteristics
Characteristics of 335 case mothers and 263 control mothers, with p-values computed using Fisher’s exact test
of independence of rows and columns.
Cases Controls
N (%) N (%) p-value
Age (yrs)
  <30 206 (61.5) 160 (60.8)
  >=30 128 (38.2) 103 (39.2)
  Missing 1 (0.3) 0 (0.0) 0.925
Race
  Caucasian 257 (76.7) 199 (75.7)
  African America 49 (14.6) 36 (13.7)
  Hispanic 24 (7.2) 23 (8.7)
  Others 4 (1.2) 5 (1.9)
  Missing 1 (0.3) 0 (0.0) 0.833
Smoker
  No 252 (75.2) 208 (79.1)
  Yes 81 (24.2) 53 (20.2)
  Missing 2 (0.6) 2 (0.8) 0.497
Alcohol drinker
  No 89 (26.6) 88 (33.5)
  Yes 241 (71.9) 167 (63.5)
  Missing 5 (1.5) 8 (3.0) 0.064
Vitamin supplementation
  No 230 (68.7) 177 (67.3)
  Yes 102 (30.4) 83 (31.6)
  Missing 3 (0.9) 3 (1.1) 0.937
BMI status
  Underweight 5 (1.5) 9 (3.4)
  Normal 118 (35.2) 106 (40.3)
  Overweight 86 (25.7) 54 (20.5)
  Obese 115 (34.3) 78 (29.7)
  Missing 11 (3.3) 16 (6.1) 0.073
Maternal Education
  College education or higher 160 (47.8) 140 (53.2)
  High school or less 162 (48.4) 108 (41.1)
  Missing 13 (3.9) 15 (5.7) 0.157
Household Income
  Less than $10,000 58 (17.3) 39 (14.8)
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Cases Controls
N (%) N (%) p-value
  $10,000 – $30,000 116 (34.6) 67 (25.5)
  $30,000 – $50,000 73 (21.8) 64 (24.3)
  More than $50,000 59 (17.6) 57 (21.7)
  Missing 29 (8.7) 36 (13.7) 0.046
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Table 3
Custom SNP Panel
Summary of custom Illumina GoldenGate genotyping panel consisting of 1536 SNPs in 62 genes involved in
the homocysteine, folate, and transsulfuration pathways.
Gene
Symbol Chromosome
Number
of SNPs Pathway
MTHFR 1 25 Folate
TYMS 18 22 Folate
TCN2 22 30 Folate
RFC1 4 32 Folate
SHMT1 17 31 Folate
MTHFD1 14 26 Folate
MTHFD2 2 18 Folate
MTHFS 15 45 Folate
DHFR 5 8 Folate
FOLR1 11 7 Folate
FOLR2 11 5 Folate
AHCYL1 1 17 Homocysteine
MTR 1 51 Homocysteine
CTH 1 30 Homocysteine
DNMT1 19 10 Homocysteine
TRDMT1 10 47 Homocysteine
DNMT3A 2 40 Homocysteine
DNMT3B 20 41 Homocysteine
DNMT3L 21 13 Homocysteine
MAT1A 10 32 Homocysteine
MAT2A 2 13 Homocysteine
MAT2B 5 28 Homocysteine
BHMT 5 19 Homocysteine
BHMT2 5 13 Homocysteine
KIAA0828 7 38 Homocysteine
COMT 22 39 Homocysteine
MTRR 5 37 Homocysteine
GNMT 6 7 Homocysteine
CBS 21 38 Transsulfuration
GSR 8 29 Transsulfuration
GCLM 1 10 Transsulfuration
GSS 20 18 Transsulfuration
PGDS 4 21 Transsulfuration
GCLC 6 60 Transsulfuration
MGST1 12 36 Transsulfuration
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Gene
Symbol Chromosome
Number
of SNPs Pathway
OGG1 3 8 Transsulfuration
GPX2 14 9 Transsulfuration
GPX3 5 29 Transsulfuration
GPX4 19 7 Transsulfuration
GPX5 6 12 Transsulfuration
GPX6 6 9 Transsulfuration
GLRX 5 32 Transsulfuration
GSTK1 7 2 Transsulfuration
NOS2A 17 35 Transsulfuration
NOS3 7 17 Transsulfuration
GSTA1 6 9 Transsulfuration
GSTA2 6 17 Transsulfuration
GSTA3 6 16 Transsulfuration
GSTA4 6 19 Transsulfuration
SOD1 21 12 Transsulfuration
SOD2 6 11 Transsulfuration
SOD3 4 12 Transsulfuration
CAT 11 41 Transsulfuration
GSTZ1 14 21 Transsulfuration
GSTM2 1 6 Transsulfuration
GSTM3 1 5 Transsulfuration
GSTM4 1 12 Transsulfuration
GSTM5 1 11 Transsulfuration
GSTO1 10 18 Transsulfuration
GSTP1 10 13 Transsulfuration
GSTT2 22 2 Transsulfuration
MGMT 10 215 Transsulfuration
Total 1536
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